Guido Zavatta1, Guido Di Dalmazi1, Carmine Pizzi2, Giovanni Bracchetti2, Cristina Mosconi3, Caterina Balacchi3, Uberto Pagotto1, Valentina Vicennati4. 1. Endocrinology Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, Alma Mater Studiorium-University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. 2. Institute of Cardiology, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. 3. Division of Radiology, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. 4. Endocrinology Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, Alma Mater Studiorium-University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. vicennati@aosp.bo.it.
Abstract
OBJECTIVE: Primary aldosteronism is associated with higher cardiovascular morbidity as compared with essential hypertension. Vascular complications encompass myocardial infarction and cerebrovascular events. Aortic damage in primary aldosteronism has never been explored, although a few cases of ascending aorta aneurisms have been reported. DESIGN AND METHODS: We consecutively enrolled patients affected by primary aldosteronism (n = 45) and compared them with patients affected by essential hypertension (n = 47), on an outpatient setting. Echocardiographic data of patients with primary aldosteronism were collected during a mean follow-up of 3 years, in subjects who underwent adrenal surgery (n = 12) and those on mineralocorticoid receptor antagonists (n = 33). RESULTS AND CONCLUSION: We found that patients with primary aldosteronism had larger ascending aorta diameters than those with essential hypertension before starting any specific treatment. Patients with primary aldosteronism did not show significant changes in the size of ascending aorta during a mean of 3 years of follow-up, irrespective of the type of treatment (medical vs. surgical treatment). A longer follow-up will better clarify if worsening of the aortic damage may be better prevented by surgery rather than by mineralocorticoid receptor antagonists.
OBJECTIVE: Primary aldosteronism is associated with higher cardiovascular morbidity as compared with essential hypertension. Vascular complications encompass myocardial infarction and cerebrovascular events. Aortic damage in primary aldosteronism has never been explored, although a few cases of ascending aorta aneurisms have been reported. DESIGN AND METHODS: We consecutively enrolled patients affected by primary aldosteronism (n = 45) and compared them with patients affected by essential hypertension (n = 47), on an outpatient setting. Echocardiographic data of patients with primary aldosteronism were collected during a mean follow-up of 3 years, in subjects who underwent adrenal surgery (n = 12) and those on mineralocorticoid receptor antagonists (n = 33). RESULTS AND CONCLUSION: We found that patients with primary aldosteronism had larger ascending aorta diameters than those with essential hypertension before starting any specific treatment. Patients with primary aldosteronism did not show significant changes in the size of ascending aorta during a mean of 3 years of follow-up, irrespective of the type of treatment (medical vs. surgical treatment). A longer follow-up will better clarify if worsening of the aortic damage may be better prevented by surgery rather than by mineralocorticoid receptor antagonists.
Authors: V Palmieri; J N Bella; D K Arnett; M J Roman; A Oberman; D W Kitzman; P N Hopkins; M Paranicas; D C Rao; R B Devereux Journal: Hypertension Date: 2001-05 Impact factor: 10.190
Authors: Loren F Hiratzka; George L Bakris; Joshua A Beckman; Robert M Bersin; Vincent F Carr; Donald E Casey; Kim A Eagle; Luke K Hermann; Eric M Isselbacher; Ella A Kazerooni; Nicholas T Kouchoukos; Bruce W Lytle; Dianna M Milewicz; David L Reich; Souvik Sen; Julie A Shinn; Lars G Svensson; David M Williams Journal: Circulation Date: 2010-03-16 Impact factor: 29.690
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: Dien Ye; Congqing Wu; Hui Chen; Ching-Ling Liang; Deborah A Howatt; Michael K Franklin; Jessica J Moorleghen; Samuel C Tyagi; Estrellita Uijl; A H Jan Danser; Hisashi Sawada; Alan Daugherty; Hong S Lu Journal: Biomolecules Date: 2022-06-13